Business & regional news

-- Nexpowder™* provides gastroenterologists improved visibility, controls upper gastrointestinal (GI) bleeding effectively and with ease^1,2,3 --

-- Nexpowder™* endoscopic hemostasis system showed a lower rebleeding rate and has nearly double the adhesive force of other hemostatic sprays^2,3 --

Medtronic been ranked fifth in the 2022 Best Workplaces in Asia list by Great Place to Work, the global authority on workplace culture. This is a significant improvement of six places from 2021....

Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...

Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...

TCT 2022: Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets Medtronic today announced findings from its Pathological Study of Hypo-Attenuated...

TCT 2022: Medtronic Unveils Latest Transcatheter Aortic Valve Replacement Data in Late-Breaking Clinical Science and Presentations

George Murgatroyd, general manager and vice president of Digital Surgery at Medtronic, will join Kimberly Powell, vice president of Healthcare and Life Sciences at NVIDIA, in a fireside chat at NVIDIA

Medtronic plc, a global leader in healthcare technology, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for the RespArray™ patient monitor designed for procedural sedation and medical-surgical units.

Combination of InPen™ smart insulin pen system integrated with Guardian™ 4 CGM helps people with diabetes on multiple daily injections (MDI) stay ahead of their glucose levels^i,ii